<p><strong>资深高管带来四十年的金融、资本市场和生命科学经验</strong></p>
<p>北卡罗来纳州达勒姆，2025 年 12 月 23 日（全球新闻通讯社）-- Pelthos Therapeutics Inc.（纽约证券交易所：PTHS），一家致力于商业化创新治疗产品以满足未满足患者需求的生物制药公司（“Pelthos”），今天宣布已任命资深金融高管 Andrew J. Einhorn 为其董事会成员，立即生效。Einhorn 先生将在 Pelthos 的 2026 年股东年会上任期结束之前，或在其继任者当选并合格之前，或在其提前辞职或被免职之前，继续担任董事会成员。此外，Einhorn 先生还将立即担任 Pelthos 董事会的审计委员会和薪酬委员会成员。</p>
<p>Einhorn 先生在投资银行和资本市场方面拥有超过四十年的经验，以及在快速发展的临床和商业阶段生命科学公司担任 C 级金融职务的丰富企业财务管理经验。</p>
<p>“Andrew 在资本市场和内部财务方面的丰富经验使他成为 Pelthos 董事会的强大补充，” 董事会主席 Peter Greenleaf 表示。“他在多家上市和私营生命科学公司加速公司增长的经验将对 Pelthos 作为一家以商业为重点的公司成长至关重要。”</p>
<p>随着 Einhorn 先生的加入，Pelthos 董事会的成员增加至八位。</p>
<p>Einhorn 先生目前担任 Danforth Advisors 的顾问，为公共和私营生命科学公司提供高水平的战略财务指导。在加入 Danforth 之前，Einhorn 先生曾在多家临床和商业阶段的生物技术公司担任首席财务官，包括 ESP Pharma、Esprit Pharma、Oceana Therapeutics、Edge Therapeutics 和 RVL Pharmaceuticals，在该行业工作了 20 年。他之前在资本市场和投资银行工作超过 20 年。目前，他还担任以色列生物技术基金的风险顾问。</p>
<p>“我很高兴能与这一杰出的行业高管团队合作，在 Pelthos 董事会的新角色中帮助指导 Pelthos，” Einhorn 先生表示。“我相信 Pelthos 作为一家新上市公司已经有了一个良好的开端，我期待与董事会合作，提升 Pelthos 在未来的使命。”</p>
<p><strong>关于 Pelthos Therapeutics</strong></p>
<p>Pelthos Therapeutics 是一家致力于商业化创新、安全和有效的治疗产品，以帮助面临未满足治疗负担的患者的生物制药公司。该公司的主打产品 ZELSUVMI™（berdazimer）外用凝胶，浓度 10.3%，用于治疗软疣，已于 2024 年获得美国食品药品监督管理局的批准。更多信息请访问 www.pelthos.com。关注 Pelthos 的 LinkedIn 和 X。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明，按照 1934 年证券交易法第 21E 条的定义，涉及 Pelthos 当前的预期。所有声明，除了历史事实的陈述外，都可能被视为前瞻性声明。在某些情况下，诸如 “计划”、“相信”、“期望”、“预期” 和 “将” 等词语及类似表达，旨在识别前瞻性声明。读者被警告不要对这些前瞻性声明过于依赖，这些声明反映了我们的善意信念（或相关第三方的信念），并仅在本声明日期有效。这些前瞻性声明包括但不限于，关于（i）Einhorn 先生的资本市场和内部财务经验使他成为 Pelthos 董事会的强大补充的预期，（ii）Einhorn 先生在多家上市和私营生命科学公司加速公司增长的经验对 Pelthos 作为一家以商业为重点的公司成长的影响，以及（iii）Einhorn 先生相信 Pelthos 作为一家新上市公司已经有了良好的开端及其对未来提升 Pelthos 使命的预期。这些声明并不保证未来的表现，并且受到某些风险、不确定性和假设的影响，这些因素难以预测。可能导致实际结果与这些前瞻性声明中所述结果显著不同的因素包括但不限于，与我们依赖第三方合作伙伴进行市场准入和分销相关的风险和不确定性；ZELSUVMI 可能未能获得市场接受或广泛的处方覆盖的可能性；我们维持监管批准的能力；以及一般经济条件的变化，包括由于战争、冲突、流行病、关税实施以及正在进行或未来的诉讼可能使我们面临重大责任并对我们产生重大不利影响。这些及其他风险和不确定性在我们向美国证券交易委员会提交的文件中有更详细的描述。本新闻稿中的信息仅在本新闻稿日期有效，我们不承担根据新信息、未来事件或其他情况更新本新闻稿中包含的任何前瞻性声明的义务，除非法律要求。</p>
<p><strong>联系方式</strong></p>
<p>投资者：</p>
<p>LifeSci Advisors, LLC</p>
<p>Mike Moyer，董事总经理</p>
<p>mmoyer@lifesciadvisors.com</p>
<p>媒体：</p>
<p>KWM Communications</p>
<p>Kellie Walsh</p>
<p>pelthos@kwmcommunications.com</p>
<p>(914) 315-6072</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZzBOQ00zTXpNMU5EUTFJelV3TURFeU5qY3hPUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZzBOQ00zTXpNMU5EUTFJelV3TURFeU5qY3hPUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NjkwODZiOWUtZjY2NS00Yzc3LThiZjAtODFkMTNmMGE2YzE0LTUwMDEyNjcxOS0yMDI1LTEyLTIzLWVu/tiny/Pelthos-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NjkwODZiOWUtZjY2NS00Yzc3LThiZjAtODFkMTNmMGE2YzE0LTUwMDEyNjcxOS0yMDI1LTEyLTIzLWVu/tiny/Pelthos-Therapeutics-Inc-.png"/></p>

PTHS

<p>Pelthos Therapeutics 已任命 Andrew J. Einhorn 为董事会成员，立即生效。Einhorn 拥有四十年的金融和生命科学经验，还将担任审计委员会和薪酬委员会的成员。他的专业知识预计将有助于 Pelthos 作为一家以商业为导向的公司的增长。董事会目前有八名董事。Einhorn 是 Danforth Advisors 的顾问，并曾在多家生物科技公司担任首席财务官。他对作为一家新上市公司为 Pelthos 的使命做出贡献感到兴奋</p>

<p><strong>Seasoned executive brings four decades of finance, capital markets, and life sciences experience</strong></p>
<div class="lb-trans"><p><strong>资深高管带来四十年的金融、资本市场和生命科学经验</strong></p>
</div><p>DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos’ 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors.</p>
<div class="lb-trans"><p>北卡罗来纳州达勒姆，2025 年 12 月 23 日（全球新闻通讯社）-- Pelthos Therapeutics Inc.（纽约证券交易所：PTHS），一家致力于商业化创新治疗产品以满足未满足患者需求的生物制药公司（“Pelthos”），今天宣布已任命资深金融高管 Andrew J. Einhorn 为其董事会成员，立即生效。Einhorn 先生将在 Pelthos 的 2026 年股东年会上任期结束之前，或在其继任者当选并合格之前，或在其提前辞职或被免职之前，继续担任董事会成员。此外，Einhorn 先生还将立即担任 Pelthos 董事会的审计委员会和薪酬委员会成员。</p>
</div><p>Mr. Einhorn brings extensive corporate financial management experience to the role, with more than four decades of experience in investment banking and capital markets, as well as in C-level finance roles at fast-paced clinical and commercial-stage life science companies.</p>
<div class="lb-trans"><p>Einhorn 先生在投资银行和资本市场方面拥有超过四十年的经验，以及在快速发展的临床和商业阶段生命科学公司担任 C 级金融职务的丰富企业财务管理经验。</p>
</div><p>“Andrew’s extensive capital markets and in-house finance experience make him a strong addition to the Pelthos Board of Directors,” said Peter Greenleaf, Chairman of the Board. “His experience accelerating company growth at multiple public and private life science companies will be critical as Pelthos grows as a commercially focused company.”</p>
<div class="lb-trans"><p>“Andrew 在资本市场和内部财务方面的丰富经验使他成为 Pelthos 董事会的强大补充，” 董事会主席 Peter Greenleaf 表示。“他在多家上市和私营生命科学公司加速公司增长的经验将对 Pelthos 作为一家以商业为重点的公司成长至关重要。”</p>
</div><p>With the addition of Mr. Einhorn, the Pelthos Board has increased to eight directors.</p>
<div class="lb-trans"><p>随着 Einhorn 先生的加入，Pelthos 董事会的成员增加至八位。</p>
</div><p>Mr. Einhorn currently serves as a consultant at Danforth Advisors, providing high-level strategic financial guidance to public and private life science companies. Before joining Danforth, Mr. Einhorn served as Chief Financial Officer at multiple clinical and commercial-stage biotechnology companies, including ESP Pharma, Esprit Pharma, Oceana Therapeutics, Edge Therapeutics and RVL Pharmaceuticals, over his 20-year tenure in the industry. He previously worked in capital markets and investment banking for more than 20 years. He currently serves as a venture advisor to the Israel Biotech Fund.</p>
<div class="lb-trans"><p>Einhorn 先生目前担任 Danforth Advisors 的顾问，为公共和私营生命科学公司提供高水平的战略财务指导。在加入 Danforth 之前，Einhorn 先生曾在多家临床和商业阶段的生物技术公司担任首席财务官，包括 ESP Pharma、Esprit Pharma、Oceana Therapeutics、Edge Therapeutics 和 RVL Pharmaceuticals，在该行业工作了 20 年。他之前在资本市场和投资银行工作超过 20 年。目前，他还担任以色列生物技术基金的风险顾问。</p>
</div><p>“I am excited to work alongside this distinguished group of industry executives to help guide Pelthos in my new role on Pelthos’ Board of Directors,” said Mr. Einhorn. “I believe Pelthos is already off to a strong start as a new publicly traded company, and I look forward to collaborating with the Board of Directors to enhance the Pelthos mission for the bright future ahead.”</p>
<div class="lb-trans"><p>“我很高兴能与这一杰出的行业高管团队合作，在 Pelthos 董事会的新角色中帮助指导 Pelthos，” Einhorn 先生表示。“我相信 Pelthos 作为一家新上市公司已经有了一个良好的开端，我期待与董事会合作，提升 Pelthos 在未来的使命。”</p>
</div><p><strong>About Pelthos Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Pelthos Therapeutics</strong></p>
</div><p>Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.</p>
<div class="lb-trans"><p>Pelthos Therapeutics 是一家致力于商业化创新、安全和有效的治疗产品，以帮助面临未满足治疗负担的患者的生物制药公司。该公司的主打产品 ZELSUVMI™（berdazimer）外用凝胶，浓度 10.3%，用于治疗软疣，已于 2024 年获得美国食品药品监督管理局的批准。更多信息请访问 www.pelthos.com。关注 Pelthos 的 LinkedIn 和 X。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) Mr. Einhorn’s capital markets and in-house finance experience making him a strong addition to the Pelthos Board of Directors, (ii) the impact Mr. Einhorn’s experience accelerating company growth at multiple public and private life science companies will have on Pelthos as it grows as a commercially focused company, and (iii) Mr. Einhorn’s belief that Pelthos is already off to a strong start as a new publicly traded company and his expectations with respect to enhancing the Pelthos mission in the future. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to our reliance on third-party partners for market access and distribution; the possibility that ZELSUVMI may not achieve market acceptance or broad formulary coverage; our ability to maintain regulatory approvals; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，按照 1934 年证券交易法第 21E 条的定义，涉及 Pelthos 当前的预期。所有声明，除了历史事实的陈述外，都可能被视为前瞻性声明。在某些情况下，诸如 “计划”、“相信”、“期望”、“预期” 和 “将” 等词语及类似表达，旨在识别前瞻性声明。读者被警告不要对这些前瞻性声明过于依赖，这些声明反映了我们的善意信念（或相关第三方的信念），并仅在本声明日期有效。这些前瞻性声明包括但不限于，关于（i）Einhorn 先生的资本市场和内部财务经验使他成为 Pelthos 董事会的强大补充的预期，（ii）Einhorn 先生在多家上市和私营生命科学公司加速公司增长的经验对 Pelthos 作为一家以商业为重点的公司成长的影响，以及（iii）Einhorn 先生相信 Pelthos 作为一家新上市公司已经有了良好的开端及其对未来提升 Pelthos 使命的预期。这些声明并不保证未来的表现，并且受到某些风险、不确定性和假设的影响，这些因素难以预测。可能导致实际结果与这些前瞻性声明中所述结果显著不同的因素包括但不限于，与我们依赖第三方合作伙伴进行市场准入和分销相关的风险和不确定性；ZELSUVMI 可能未能获得市场接受或广泛的处方覆盖的可能性；我们维持监管批准的能力；以及一般经济条件的变化，包括由于战争、冲突、流行病、关税实施以及正在进行或未来的诉讼可能使我们面临重大责任并对我们产生重大不利影响。这些及其他风险和不确定性在我们向美国证券交易委员会提交的文件中有更详细的描述。本新闻稿中的信息仅在本新闻稿日期有效，我们不承担根据新信息、未来事件或其他情况更新本新闻稿中包含的任何前瞻性声明的义务，除非法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Investors:</p>
<div class="lb-trans"><p>投资者：</p>
</div><p>LifeSci Advisors, LLC</p>
<div class="lb-trans"><p>LifeSci Advisors, LLC</p>
</div><p>Mike Moyer, Managing Director</p>
<div class="lb-trans"><p>Mike Moyer，董事总经理</p>
</div><p>mmoyer@lifesciadvisors.com</p>
<div class="lb-trans"><p>mmoyer@lifesciadvisors.com</p>
</div><p>Media:</p>
<div class="lb-trans"><p>媒体：</p>
</div><p>KWM Communications</p>
<div class="lb-trans"><p>KWM Communications</p>
</div><p>Kellie Walsh</p>
<div class="lb-trans"><p>Kellie Walsh</p>
</div><p>pelthos@kwmcommunications.com</p>
<div class="lb-trans"><p>pelthos@kwmcommunications.com</p>
</div><p>(914) 315-6072</p>
<div class="lb-trans"><p>(914) 315-6072</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZzBOQ00zTXpNMU5EUTFJelV3TURFeU5qY3hPUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjg0NCM3MzM1NDQ1IzUwMDEyNjcxOQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NjkwODZiOWUtZjY2NS00Yzc3LThiZjAtODFkMTNmMGE2YzE0LTUwMDEyNjcxOS0yMDI1LTEyLTIzLWVu/tiny/Pelthos-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NjkwODZiOWUtZjY2NS00Yzc3LThiZjAtODFkMTNmMGE2YzE0LTUwMDEyNjcxOS0yMDI1LTEyLTIzLWVu/tiny/Pelthos-Therapeutics-Inc-.png"/></p>

Pelthos Therapeutics 通过任命 Andrew Einhorn 扩展董事会 | PTHS 股票新闻